Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tabalumab Biomarker Study in Rheumatoid Arthritis
NCT01576549Phase 2Terminated
- Sponsor
- Eli Lilly and Company
- Start
- May 2012
- Primary completion
- May 2013
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tabalumab in rheumatoid arthritis (RA), sponsored by Eli Lilly and Company. Started May 2012; status: terminated.
02
Drugs
tabalumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT01576549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01576549.